- Home
- CGON vs ALTM Comparison
CGON vs ALTM Comparison
Compare CGON & ALTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- ALTM
- Stock Information
- Founded
- CGON 2010
- ALTM 1942
- Country
- CGON United States
- ALTM Ireland
- Employees
- CGON 61
- ALTM N/A
- Industry
- CGON
- ALTM
- Sector
- CGON
- ALTM
- Exchange
- CGON NYSE
- ALTM Nasdaq
- Market Cap
- CGON 2.2B
- ALTM 2.6B
- IPO Year
- CGON 2024
- ALTM N/A
- Fundamental
- Price
- CGON $32.84
- ALTM $5.23
- Analyst Decision
- CGON Strong Buy
- ALTM Hold
- Analyst Count
- CGON 8
- ALTM 16
- Target Price
- CGON $63.88
- ALTM $5.51
- AVG Volume (30 Days)
- CGON 396.6K
- ALTM 16.0M
- Earning Date
- CGON 11-12-2024
- ALTM 11-07-2024
- Dividend Yield
- CGON N/A
- ALTM N/A
- EPS Growth
- CGON N/A
- ALTM N/A
- EPS
- CGON N/A
- ALTM 0.16
- Revenue
- CGON $684,000.00
- ALTM $900,600,000.00
- Revenue This Year
- CGON $411.76
- ALTM $22.72
- Revenue Next Year
- CGON $405.27
- ALTM $13.85
- P/E Ratio
- CGON N/A
- ALTM $33.55
- Revenue Growth
- CGON 258.12
- ALTM N/A
- 52 Week Low
- CGON $25.77
- ALTM $2.19
- 52 Week High
- CGON $50.23
- ALTM $7.80
- Technical
- Relative Strength Index (RSI)
- CGON 41.08
- ALTM 60.07
- Support Level
- CGON $35.12
- ALTM $5.20
- Resistance Level
- CGON $40.47
- ALTM $5.47
- Average True Range (ATR)
- CGON 1.69
- ALTM 0.08
- MACD
- CGON -0.28
- ALTM -0.11
- Stochastic Oscillator
- CGON 4.57
- ALTM 8.93
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About ALTM Arcadium Lithium plc
Arcadium Lithium is a pure-play lithium producer that was formed in the Allkem-Livent merger in January 2024. Arcadium should benefit from increased lithium demand via higher electric vehicle adoption, as lithium is a key component of EV batteries. The company's low-cost lithium carbonate production comes from two brine resources in Argentina. Arcadium also produces spodumene, a hard rock lithium upstream concentrate, from a mine in Australia and operates downstream lithium hydroxide conversion plants in the United States and China.